Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphomafor High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements86 locations incl. Los AngelesSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06649812·Phase 2·RecruitingApply to this trial
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancerfor Metastatic Nasopharyngeal CarcinomaDrug: Relatlimab83 locations incl. DublinSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06029270·Phase 2·RecruitingApply to this trial
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesotheliomafor Pleural Biphasic Mesothelioma132 locations incl. AnchorageSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT05647265·Phase 2·RecruitingApply to this trial